Australia's largest stock trading and investment forum Australia's #1 stock forum

RXH

Click for more information

0.00%

2.9¢ rewardle holdings limited

Ann: Response to ASX Appendix 4C Query, page-3

First 3 Last

Share
Profile

Follow
Greenspan

55 Posts.

1

27/02/19

09:35

Post #: 37581752
Share

Originally posted by haozhijiang: ↑

How far is the next round of R&D grant? It looks like RXH is moving towards the VA as its cash flow has less than one month to go. The placement of the shortfall shares is a must and Rewan has to top up more from his own pocket. the debt collection is a decoit as it is only $100k
which is not of a significant value.

The merchant number has been stagnant for quite some time with over 3m members.

RXH has changed a lot and so does the market in the last 5 years. I think RXH has missed the boat unfortunately and it is unlikely to be a turn back story. All the small caps are running into such a dry market and the worst is yet to come.

Expand

R&D application needs to be in by April 30. Then takes 1-2 months to be processed. This is worst case, they may have already submitted it.

With the crackdown of Airtasker etc and the reduction in R&D expenses it will no doubt be smaller than previous years.

RXH Price at posting: 0.4¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 3 more messages in this thread...

First 3 Last

Add RXH (ASX) to my watchlist